- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05794217
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
This protocol will be utilized to collect research grade products that are not meant for transfusion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center study, with up to 20,000 participants enrolled. Participants may complete up to two visits, a screening visit, and an apheresis visit, during their enrollment in the study.
The biospecimens collected by apheresis may be processed and stored, delivered frozen, or delivered unfrozen directly to the requesting researcher. All participant specimens, if processed, will be stored, and distributed to researchers in an anonymized fashion.
The following activities will occur during the study:
Sponsor Obtain overall study informed consent. Sanguine will implement a software-as-a-service (SaaS) provider of electronic signature technology and transaction management solutions and/or a hardcopy of the informed consent form (ICF). Participants may electronically sign the ICF and authorization of release of information using an electronic device. The Sponsor will also provide the participant the option of completing hardcopy documents if they so desire. In addition to the Principal Investigator (PI), approved study staff can also administer and sign the ICF and will address all of the participant's queries regarding the ICF and study design. The informed consent process can take place at the site location by the on-site staff. In addition to the overall study informed consent, sites may also administer their own ICF per site-specific procedures, if required.
Health information will be collected via self-report and medical record review to obtain a detailed clinical history of the subject's health. The health information includes but is not limited to demographic and lifestyle information, height and weight, current medications and comorbidities, date of diagnosis, condition-related treatment history, current disease characteristics, diagnostic reports, and family medical history.
Apheresis Center Laboratory tests, including, but not limited to, a complete blood count (CBC) and viral testing for hepatitis C, hepatitis B, and HIV, at a minimum, will be performed on all prospective donors.
Apheresis health questionnaire to identify potential health risks and risk of communicable disease.
Venous access check completed by an apheresis nurse to qualify donor as having adequate veins for successful apheresis.
Assessment performed by the apheresis collection center on the day of donation which may include (but is not limited to the following) Basic health questionnaire to assess donor suitability for apheresis Mini physical exam including vitals and hemoglobin measurement Other requirements of the apheresis center as per standard procedure Apheresis cell collection
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Recruiting
- Sanguine Biosciences
-
Contact:
- Sonia Lunar
- Phone Number: 855-836-4759
- Email: slunar@sanguinebio.com
-
Principal Investigator:
- Timothy Triche, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Persons deemed healthy enough for the procedure and aged 18 to 89 years at the date of informed consent.
Minimum weight of 110 lbs. Pulse greater than 50 and less than 110 beats per minute Blood Pressure diastolic greater than 50 mmHg and less than100 mmHG and systolic is greater than 90 mmHg and less than 180 mmHg Peripheral veinous access is deemed adequate for apheresis as determined by apheresis staff.
Negative for Hepatitis B, Hepatitis C, and HIV 1-2 upon testing performed within 30 days, unless specifically obtaining cell collection based upon this diagnosis.
CBC results which fall within site-specific parameters within 30 days of apheresis procedure:
The participant understands the procedures and requirements of the study by providing written informed consent, including consent for authorization for protected health information disclosure.
Exclusion Criteria:
- Persons younger than 18 years of age or older than 89 years of age at the date of informed consent.
Presenting with a history of a specific condition determined through medical evaluation to be incompatible with safely undergoing apheresis Receipt of transfusion of blood products within 30 days of the study procedure. Receipt of an investigational (unapproved) drug 30 days before the study procedure.
A confirmable diagnosis of any medical condition that would increase potential procedure risks. Such medical conditions include:
Severe or untreated cardiovascular, kidney, liver, or lung diseases which would preclude apheresis procedures; Bleeding disorders Conditions associated with chronic anemia Active systemic infection Use of ACE inhibitors unless they can safely be held for 24 hours prior to apheresis procedure Pregnancy Has donated a unit of blood within the last 2 months at the date of informed consent.
Unable to understand the procedures and requirements of the study in order to provide written informed consent, including consent for authorization for protected health information disclosure.
Requires a Legally Authorized Representative (LAR) for the study informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leukopak
Time Frame: September 2022 and September 2024
|
The studies collected biospecimens are white blood cells, specifically leukopaks.
|
September 2022 and September 2024
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAN-BB-LEUK-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rare Diseases
-
Seoul National University HospitalRecruitingGenetic Rare DiseaseKorea, Republic of
-
Prisma Health-UpstateAstraZeneca; MedImmune LLCRecruitingCancer | Rare DiseaseUnited States
-
University Hospital, Strasbourg, FranceRecruiting
-
Scripps Translational Science InstituteEnrolling by invitation
-
Shandong UniversityNational Health Medical Data (North Center)Recruiting
-
BioMarin PharmaceuticalUnknownRare Genetic DisordersUnited States
-
Wuerzburg University HospitalHannover Medical School; Goethe University; University Hospital Tuebingen; Universitätsklinikum... and other collaboratorsCompletedRare Diseases | Orphan DiseasesGermany
-
Swedish Orphan BiovitrumCompleted
-
Illumina, Inc.Children's Hospital of Philadelphia; St. Louis Children's Hospital; Children's... and other collaboratorsCompleted
-
Federal University of Health Science of Porto AlegreUnknownCardiovascular DiseasesBrazil
Clinical Trials on This is a non-interventional study
-
Hull University Teaching Hospitals NHS TrustUniversity of YorkRecruiting
-
Amicus TherapeuticsEngage Health Inc.CompletedFabry DiseaseUnited States
-
University Hospital HeidelbergCompletedEmergencies | COVID-19 PandemicGermany
-
University of MalayaMichael J. Fox Foundation for Parkinson's Research; University of Dundee; Nextcea... and other collaboratorsUnknown
-
International Institute of Behavioral MedicinesRecruiting
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
KK Women's and Children's HospitalUniversity of PlymouthActive, not recruitingCritical Illness | Pediatric ALL | Post Intensive Care Unit SyndromeSingapore
-
Notable LabsCompletedLymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative NeoplasmSpain, United States, Greece
-
Medlior Health Outcomes Research LtdCompletedChronic Kidney Diseases | Type 2 Diabetes
-
University Hospital of CologneClinic for Internal Medicine I, University Hospital Cologne, Germany; Institute... and other collaboratorsUnknownCOVID-19 | SARS-CoV-2Germany